Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK , OCT. 28, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFLARIMAR THERAPEUTICS, INC.("LARIMAR" OR THE "COMPANY")(NASDAQ: LRMR).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF LARIMAR THERAPEUTICS, INC. - LRMR

NEW YORK , OCT. 23, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFLARIMAR THERAPEUTICS, INC.("LARIMAR" OR THE "COMPANY")(NASDAQ: LRMR).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK , OCT. 18, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFLARIMAR THERAPEUTICS, INC.("LARIMAR" OR THE "COMPANY")(NASDAQ: LRMR).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

LOS ANGELES , OCT. 16, 2025 /PRNEWSWIRE/ --THE DJS LAW GROUPANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFLARIMAR THERAPEUTICS, INC. ("LARIMAR" OR "THE COMPANY") (NASDAQ: LRMR) FOR VIOLATIONS OF THE SECURITIES LAWS. INVESTIGATION DETAILS: THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.

LARIMAR THERAPEUTICS, INC. INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - LRMR

LOS ANGELES--(BUSINESS WIRE)--LARIMAR THERAPEUTICS, INC. INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  LRMR.

LARIMAR THERAPEUTICS, INC. INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  LRMR

NEW YORK , OCT. 13, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFLARIMAR THERAPEUTICS, INC.("LARIMAR" OR THE "COMPANY")(NASDAQ: LRMR).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK , OCT. 8, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFLARIMAR THERAPEUTICS, INC.("LARIMAR" OR THE "COMPANY")(NASDAQ: LRMR).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

BALA CYNWYD, PA., SEPT. 29, 2025 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES, TODAY ANNOUNCED POSITIVE 25 MG AND 50 MG DATA FROM THE ONGOING LONG-TERM OPEN LABEL (OL) STUDY EVALUATING DAILY SUBCUTANEOUS INJECTIONS OF NOMLABOFUSP SELF-ADMINISTERED OR ADMINISTERED BY A CAREGIVER IN PARTICIPANTS WITH FRIEDREICH'S ATAXIA (FA), A RARE, PROGRESSIVE, AND SYSTEMIC DISEASE WITH NEUROLOGIC DETERIORATION. THE COMPANY ALSO PROVIDED A NOMLABOFUSP DEVELOPMENT PROGRAM UPDATE.

LARIMAR THERAPEUTICS ANNOUNCES POSITIVE DATA FROM ONGOING LONG-TERM OPEN LABEL STUDY AND UPDATES TO NOMLABOFUSP PROGRAM FOR FRIEDREICH'S ATAXIA

CONFERENCE CALL AND WEBCAST ON MONDAY, SEPTEMBER 29, 2025 AT 8:00 AM EDT CONFERENCE CALL AND WEBCAST ON MONDAY, SEPTEMBER 29, 2025 AT 8:00 AM EDT

LARIMAR THERAPEUTICS ANNOUNCES CONFERENCE CALL ON THE NOMLABOFUSP PROGRAM FOR THE TREATMENT OF FRIEDREICH'S ATAXIA

* PRO FORMA CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $203.6 MILLION REFLECTS $138.5 MILLION OF CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2025 COMBINED WITH THE $65.1 MILLION IN NET PROCEEDS FROM THE RECENTLY COMPLETED JULY 2025 PUBLIC OFFERING.

LARIMAR THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

BALA CYNWYD, PA., JULY 31, 2025 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 21,562,500 SHARES OF ITS COMMON STOCK, WHICH INCLUDES THE EXERCISE IN FULL OF THE UNDERWRITERS' OPTION TO PURCHASE 2,812,500 ADDITIONAL SHARES, AT THE PUBLIC OFFERING PRICE OF $3.20 PER SHARE. THE AGGREGATE GROSS PROCEEDS TO LARIMAR FROM THIS OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES, WERE $69.0 MILLION.

LARIMAR THERAPEUTICS ANNOUNCES CLOSING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK AND EXERCISE IN FULL OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

Larimar Therapeutics, Inc.

LRMR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Larimar Therapeutics, Inc.

LRMR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LRMR